{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:38:36Z","timestamp":1767109116174,"version":"3.37.3"},"reference-count":0,"publisher":"Association of Basic Medical Sciences of FBIH","license":[{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020770","name":"Young Medical Key Talents Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["QNRC2016163"],"award-info":[{"award-number":["QNRC2016163"]}],"id":[{"id":"10.13039\/501100020770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bosn J of Basic Med Sci"],"abstract":"<jats:p>Objective: To investigate the levels of plasma exosome-derived fragile-site associated tumor suppressor (FATS) and evaluate its predictive ability in ovarian cancer (OC) patients.\r\nPatients and Methods: Exosome-rich fractions were isolated from the plasma of enrolled 90 patients with OC. The levels of plasma exosome-derived FATS were detected with ELISA.\r\nResults: The levels of exosome-derived FATS in OC patient were significantly lower than in healthy controls (P &lt; 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with low grade (1\/2), FIGO stages I\/II than high grade (3\/4), stages III\/ IV disease (P = 0.003; P &lt; 0.001). The levels of plasma exosome-derived FATS were significantly higher in OC patients with no lymph node metastasis, no ascites than those with lymph node metastasis, ascites (both P &lt; 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with CA-125 less than 35U\/ml than more than 35U\/ml (P &lt; 0.001). Among all enrolled OC patients, both 5-DFS and 5-OS were shorter in patients who had low plasma exosome-derived FATS levels than that high levels (both P &lt; 0.001). The AUROC of plasma exosome-derived FATS were 0.85(95% CI: 0.76-0.91) for 5-DFS, 0.91(95% CI: 0.83-0.96) for 5-OS prediction in patients with OC, respectively.\r\nConclusions: Plasma exosome-derived FATS levels in OC patient were significantly down-regulated. Low levels of plasma exosome-derived FATS had close relationship with FIGO stages I\/II, low grade, ascites, higher levels of CA-125, lymph node metastasis and prognosis of OC patients. Our findings may provide a new strategy in treating OC.<\/jats:p>","DOI":"10.17305\/bjbms.2021.6404","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T17:47:34Z","timestamp":1631036854000},"source":"Crossref","is-referenced-by-count":2,"title":["Plasma exosome-derived fragile-site associated tumor suppressor is a powerful predictor of prognosis in patients with ovarian cancer"],"prefix":"10.17305","author":[{"given":"Renjing","family":"Ju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6922","published-online":{"date-parts":[[2021,9,7]]},"container-title":["Bosnian Journal of Basic Medical Sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/6404\/2376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/6404\/2376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T17:47:35Z","timestamp":1631036855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bjbms.org\/ojs\/index.php\/bjbms\/article\/view\/6404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.17305\/bjbms.2021.6404","relation":{},"ISSN":["1840-4812","1512-8601"],"issn-type":[{"type":"electronic","value":"1840-4812"},{"type":"print","value":"1512-8601"}],"subject":[],"published":{"date-parts":[[2021,9,7]]}}}